🇺🇸 FDA
Pipeline program

A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).

He Huang

Unknown small_molecule completed

Quick answer

A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2). for Neuromuscular Blockade is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Neuromuscular Blockade
Phase
Unknown
Modality
small_molecule
Status
completed

Clinical trials